## **ORAL PRESENTATION**



**Open Access** 

# Evidence for Env-V2 sieve effect in breakthrough SIV MAC251 infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs

S Sina<sup>2</sup>, S Tovanabutra<sup>2</sup>, E Sanders-Buell<sup>2</sup>, A Bates<sup>2</sup>, M Bose<sup>2</sup>, S Howell<sup>2</sup>, G Ibitamuno<sup>2</sup>, M Lazzaro<sup>2</sup>, A O'Sullivan<sup>2</sup>, J Lee<sup>2</sup>, T Cervenka<sup>2</sup>, J Kuroiwa<sup>2</sup>, K Baldwin<sup>2</sup>, DH Barouch<sup>1</sup>, M Robb<sup>2</sup>, R O'Connell<sup>2</sup>, NL Michael<sup>2</sup>, JH Kim<sup>2</sup>, M Rolland<sup>2\*</sup>

From AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 2012

### Background

We had previously shown that rhesus monkeys receiving Ad26/MVA and MVA/Ad26 vaccines expressing SIV<sub>SME543</sub> were protected against SIV<sub>MAC251</sub> challenge (doi:10.1038/nature10766). Protection was associated with Env-specific binding ELISA antibody responses, including V2-specific antibodies.

#### **Methods**

We amplified 66 sequences from the SIV MAC251 challenge stock, and 409 near-full length genomes from 13 vaccine and 13 control monkeys. A series of pre-specified phylogenetic and statistical tests for sieve effects was performed.

#### Results

The mean pairwise AA diversity among the 66 SIV-MAC251 Env sequences was 0.38%, and they differed from the vaccine strain SIV SME543 (Env) by 21.94%. The repeated low-dose challenge resulted in infections with an average of 1.7 founder variants - with no evidence that the vaccine restricted the number of variants (p =0.813). We explored whether the vaccine induced a sieve effect, i.e. whether breakthrough viruses differed between the vaccine and control groups. There was no difference for full-length Env sequences. Focusing on Env segments preferentially recognized by vaccinated

<sup>2</sup>U.S. Military HIV Research Program/Henry M. Jackson Foundation, Bethesda, MD, USA

Full list of author information is available at the end of the article





© 2012 Sina et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

monkeys in antibody arrays, we identified a sieve effect in the Env-V2 segment AA163-193: sequences from vaccinated animals were more divergent from the vaccine SIV<sub>SME543</sub> or from the challenge stock SIV<sub>MAC251</sub> than sequences in control animals ( $p \le 0.002$ ).

#### Conclusion

The sieve effect in Env-V2, combined with Env-V2-specific binding antibodies identified as a correlate of protection against SIV MAC251 acquisition in the study, provide evidence supporting the importance of protective responses directed against the Env-V2 region.

#### Author details

<sup>1</sup>BIDMC, Harvard Medical School, and Ragon Institute, Boston, MA, USA. <sup>2</sup>U.S. Military HIV Research Program/Henry M. Jackson Foundation, Bethesda, MD, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-O32 Cite this article as: Sina et al.: Evidence for Env-V2 sieve effect in breakthrough SIV  $_{\rm MAC251}$  infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs. Retrovirology 2012 9(Suppl 2):O32.